Pharmaceuticals
Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor
BEIJING, Aug. 3, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 inChina. JAB-21822 is Jacobio's innovative in-house small molecule anti-cancer drug, which is designed to target t...
2021-08-03 09:00
4774
Insilico Medicine and Westlake Pharma Announce Cooperation Relationship on Accelerating the Innovative Drugs R&D for Novel Coronavirus
HANGZHOU, China, Aug. 3, 2021 /PRNewswire/ -- Insilico Medicine and Westlake
Pharma announced a strategic partnership to jointly develop innovative
small-molecule drugs for Novel Coronavirus (COVID-19) today.
2021-08-03 08:00
36033
SI Group Ranks in the Top 5 Percent for Global Corporate Social Responsibility
Company Awarded Gold Rating by EcoVadis for its Sustainability Commitment SCHENECTADY, N.Y., Aug. 2, 2021 /PRNewswire/ -- SI Group, a global leader in the innovative technology of performance additives, process solutions, active pharmaceutical ingredients, and chemical intermediates, has received...
2021-08-02 22:33
3779
Bionomics Announces Plans to Conduct U.S. Initial Public Offering
ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United ...
2021-08-02 18:00
14702
Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
TIBSOVO is the first targeted therapy to show improved event-free survival and overall survival in combination with azacitidine compared to azacitidine monotherapy. Safety profile consistent with previously published data in patients with IDH1-mutated acute myeloid leukemia. The study recently ...
2021-08-02 14:00
3495
LISCure Biosciences Announces Know-How License Agreement and Stock Purchase Agreement with Mayo Clinic
SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered into a know-how license and development collaboration agreement, and stock purchase agreement with Mayo Clinic to advance LISCure's microbiome therapeutics in non-alcoholic steatohepatitis (NASH). ...
2021-08-02 11:11
1941
Luye Pharma Enters Distribution Agreement with Zuellig Pharma for Seroquel and Seroquel XR in Malaysia and Brunei, Strengthening Business Presence in Asia Pacific and Improving Access to Evidence-Based Medical Treatments for Mental Health
SUBANG JAYA, Malaysia, Aug. 2, 2021 /PRNewswire/ -- Luye Pharma Group today announced that it has entered into an agreement with Zuellig Pharma, a leading healthcare service group inAsia, under which the company grants Zuellig Pharma exclusive rights to distribute its central nervous system drugs...
2021-08-02 10:25
5687
Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
SEOUL, South Korea and SHANGHAI and HONG KONG, Aug. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics i...
2021-08-02 07:29
6467
Appendix 4C - Q4 FY21 Quarterly Cash Flow Report
Highlights: * Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial * Publication in Movement Disorders demonstrates that ATH434 reduces α–synuclein related neurodegeneration in MSA animal model * Presents to MST Access Australian Micro & Small Caps Conference ...
2021-07-30 21:05
15759
China Jo-Jo Drugstores Completes Redomiciliation Merger
HANGZHOU, China, July 30, 2021 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that th...
2021-07-30 21:00
15690
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
* Planning underway for a Phase 1 Trial to assess new immunotherapy aimed at stimulating the innate immune system to clear beta amyloid protein plaques in Alzheimer's Disease SHANGHAI and GAITHERSBURG, Md., July 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage bio...
2021-07-30 20:00
9356
EC Healthcare and Prenetics Form Strategic Partnership to Pioneer the Future of Medicine
HONG KONG, July 30, 2021 /PRNewswire/ -- EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group inHong Kong, announces that the Group signed a memorandum of understanding with Prenetics Limit...
2021-07-30 15:33
10854
EDM Council Report Uncovers Major Evolution in Data Management Practices within Pharma / Life Sciences
NEW YORK, and AACHEN, Germany, July 29, 2021 /PRNewswire/ -- EDM Council, the cross-industry trade association for data management and analytics, along with OSTHUS and Strategy&, PwC's global strategy consulting business, have released the 2021 EDM Council Global Data Management Benchmark Surve...
2021-07-29 21:10
4265
I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million
SHANGHAI and GAITHERSBURG, Md., July 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of Directors (the "Board") has authorized...
2021-07-29 20:00
7867
HanAll Biopharma Reports Second Quarter 2021 Results
* Q2'21 sales of KRW 23.4 billion increased 4% from the same period last year * Q2'21 operating profit of KRW 1.6 billion fell slightly by 3% compared to Q2'20 * H1'21 sales of KRW 51.2 billion and operating profit of 6.3 billion grew by 15% and 56% YoY [Business Performance and Financial St...
2021-07-29 18:44
11548
Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
SHANGHAI, July 29, 2021 /PRNewswire/ -- Everest Medicines
2021-07-29 18:41
5513
Daewoong Pharmaceutical Announces Camostat Achieving 50% Faster Recovery Time for Mild COVID-19 Patients Over Age of 50 in Topline Results from Phase 2B Clinical Trial
- Improvement of symptoms such as cough and dyspnea in mild patients over age 50 was reported to be as twice as fast and statistically significant in the treatment group (4 days) compared to the placebo control group (9 days). - Development is underway for potential combination therapies and nove...
2021-07-29 18:00
2073
Exyte Empowers the Biopharmaceutical Industry: First ExyCell(R) Facility Launched in Shanghai
STUTTGART, Germany and BERGISCH GLADBACH, Germany, July 29, 2021 /PRNewswire/ -- Exyte has successfully completed the construction of the first ExyCell® facility inChina, the CliniMACS Cell Factory® of Miltenyi Biotec, a global provider of integrated solutions for Advanced Therapy Medical Products...
2021-07-29 16:25
3945
Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction
SUZHOU, China, July 29, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administrat...
2021-07-29 07:46
2925
Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325
SUZHOU, China, and ROCKVILLE, Md., July 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its global licensee, UNITY Biotechnology, In...
2021-07-29 07:40
5086
Week's Top Stories
Most Reposted
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
[Picked up by 305 media titles]
2026-07-16 10:00
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 297 media titles]
2026-07-20 15:00
Singapore Tourism Board and Traveloka Renew Partnership to Welcome More Southeast Asian and Australian Travellers to Singapore
[Picked up by 291 media titles]
2026-07-17 18:18
Klook signs an expanded two-year partnership with Korea Tourism Organization
[Picked up by 288 media titles]
2026-07-16 17:49
MetaOptics to Deploy its Direct Laser Writer at the University of Arizona's Center of Semiconductor Manufacturing to Advance its U.S. Expansion
[Picked up by 287 media titles]
2026-07-22 07:30Most Read
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
2026-07-16 10:00
19719
Klook signs an expanded two-year partnership with Korea Tourism Organization
2026-07-16 17:49
14884